Literature DB >> 22878429

FabryScan: a screening tool for early detection of Fabry disease.

Kathrin Arning1, Dennis Naleschinski, Rainer Maag, Marieke Biegstraaten, Peter Kropp, Jürgen Lorenzen, Carla E M Hollak, Ivo N van Schaik, Pontus Harten, Rainald A Zeuner, Andreas Binder, Ralf Baron.   

Abstract

Fabry disease, an X-linked lipid storage disorder, is associated early morbidity and mortality. Since enzyme replacement therapy is available, accurate detection of unrecognized cases is important. Characteristic early symptoms are recurrent episodes of burning and lancinating pain in the distal extremities associated with small fiber neuropathy. The aim was to develop and validate an easy diagnostic questionnaire in combination with three simple bedside tests, the "FabryScan", for the detection of Fabry disease in patients with chronic extremity pain. Questions related to relevant clinical characteristics of Fabry disease (mainly related to pain) were compiled by Fabry specialists and pain experts. Furthermore, three bedside tests assessing sensory small and large fiber function were established. The provisional version was tested in a prospective multicenter trial of 138 patients with chronic extremity pain due to Fabry disease (n = 55), painful polyneuropathy (n = 40), and rheumatoid arthritis (n = 43). Identification of the most discriminant combinations of items for Fabry disease and their calculation of sensitivity and specificity were based on multivariate analyses. We retained only 10 questions and three bedside tests for the final version of the FabryScan. A cut-off score of 12/33 (corresponding to the number of positive points) resulted in a high proportion of correctly identified patients (76 %) with a sensitivity of 88 % and a specificity of 87 %. The FabryScan is a combination of a brief and simple questionnaire with three simple bedside tests with good discriminative value for the identification of Fabry patients in patients with chronic extremity pain.

Entities:  

Mesh:

Year:  2012        PMID: 22878429     DOI: 10.1007/s00415-012-6619-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests.

Authors:  Christopher M Florkowski
Journal:  Clin Biochem Rev       Date:  2008-08

3.  Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

Authors:  Arndt Rolfs; Tobias Böttcher; Marlies Zschiesche; Peter Morris; Bryan Winchester; Peter Bauer; Uwe Walter; Eilhard Mix; Mathias Löhr; Klaus Harzer; Ulf Strauss; Jens Pahnke; Annette Grossmann; Reiner Benecke
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

4.  The relation between small nerve fibre function, age, disease severity and pain in Fabry disease.

Authors:  Marieke Biegstraaten; Andreas Binder; Rainer Maag; Carla E M Hollak; Ralf Baron; Ivo N van Schaik
Journal:  Eur J Pain       Date:  2011-02-22       Impact factor: 3.931

5.  Misdiagnosis in Fabry disease.

Authors:  Cintia L Marchesoni; Norma Roa; Ana María Pardal; Pablo Neumann; Guillermo Cáceres; Pablo Martínez; Isaac Kisinovsky; Silvia Bianchi; Ana Lía Tarabuso; Ricardo C Reisin
Journal:  J Pediatr       Date:  2010-05       Impact factor: 4.406

6.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.

Authors:  R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka
Journal:  Pain       Date:  2006-05-11       Impact factor: 6.961

7.  Detection of a characteristic painful neuropathy in Fabry disease: a pilot study.

Authors:  Rainer Maag; Andreas Binder; Christoph Maier; Andrea Scherens; Thomas Toelle; Rolf-Detlef Treede; Ralf Baron
Journal:  Pain Med       Date:  2008-06-18       Impact factor: 3.750

8.  Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee; Shu-Chuan Chiang; Robert Dobrovolny; Ai-Chu Huang; Hui-Ying Yeh; May-Chin Chao; Shio-Jean Lin; Teruo Kitagawa; Robert J Desnick; Li-Wen Hsu
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

9.  Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Authors:  Stephen Waldek; Manesh R Patel; Maryam Banikazemi; Roberta Lemay; Philip Lee
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

10.  Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry.

Authors:  Torquil Watt; Alessandro P Burlina; Chiara Cazzorla; Dorothee Schönfeld; Maryam Banikazemi; Robert J Hopkin; Ana Maria Martins; Katherine Sims; Dana Beitner-Johnson; Fanny O'Brien; Ulla Feldt-Rasmussen
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

View more
  4 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

2.  Stratification of patients with unclassified pain in the FabryScan database.

Authors:  Julia Forstenpointner; Paul Moeller; Manon Sendel; Maren Reimer; Philipp Hüllemann; Ralf Baron
Journal:  J Pain Res       Date:  2019-07-23       Impact factor: 3.133

3.  Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.

Authors:  Juan M Politei; Didier Bouhassira; Dominique P Germain; Cyril Goizet; Antonio Guerrero-Sola; Max J Hilz; Elspeth J Hutton; Amel Karaa; Rocco Liguori; Nurcan Üçeyler; Lonnie K Zeltzer; Alessandro Burlina
Journal:  CNS Neurosci Ther       Date:  2016-03-28       Impact factor: 5.243

4.  Fabry disease; early diagnosis improves prognosis but diagnosis is often delayed.

Authors:  Jagadish Jamboti; Cynthia H Forrest
Journal:  J Nephropathol       Date:  2017-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.